Lynx1 Capital Management LP - 30 Jun 2025 SCHEDULE 13G/A Report for TScan Therapeutics, Inc. Voting Common Stock, par value $0.0001 per share (TCRX)

Filing Manager
Lynx1 Capital Management LP
Reporting Manager
Lynx1 Capital Management LP
Security
TScan Therapeutics, Inc. Voting Common Stock, par value $0.0001 per share
Symbol
TCRX
Shares outstanding
52,382,313 shares
Disclosed Ownership
7,857,347 shares
Ownership
15%
Form type
SCHEDULE 13G/A
Filing time
14 Aug 2025, 07:06:26 UTC
Date of event
30 Jun 2025
Previous filing
14 Feb 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Lynx1 Capital Management LP disclosed 15% ownership in TScan Therapeutics, Inc. Voting Common Stock, par value $0.0001 per share (TCRX) on 30 Jun 2025."

Quick Takeaways

  • Lynx1 Capital Management LP filed SCHEDULE 13G/A for TScan Therapeutics, Inc. Voting Common Stock, par value $0.0001 per share (TCRX).
  • Disclosed ownership: 15%.
  • Date of event: 30 Jun 2025.

What Changed

  • Previous schedule filing date: 14 Feb 2025.
  • Current filing was accepted on 14 Aug 2025, 07:06.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (2)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Lynx1 Capital Management LP 15% 7,857,347 0 7,857,347 /s/ Weston Nichols By: Lynx1 Capital Management GP LLC, General Partner, By: Weston Nichols, Sole Member
Weston Nichols 15% 7,857,347 0 7,857,347 /s/ Weston Nichols Weston Nichols, Individually

Sponsored